Federal Register / Vol. 65, No. 221 / Wednesday, November 15, 2000 / Notices 69033

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Iniltial Review Group,

Subcommittee A—Cancer Centers.

Date: December 7–8, 2000.

Time: 8 a.m. to 1 p.m.

Agenda: To review and evaluate grant

applications.

Place: Embassy Suites, Chevy Chase

Pavilion, 4300 Military Rd., Wisconsin at

Western Ave., Washington, DC 20015.

Contact Person: David E. Maslow, PhD,

Scientific Review Administrator, Grants

Review Branch, Division of Extramural

Activities, National Cancer Institute, National

Institutes of Health, 6116 Executive

Boulevard—Room 8054, Bethesda, MD

20892–7405, 301/496–2330.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: November 3, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–29139 Filed 11–14–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6). Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Initial Review Group, Subcommittee

D—Clinical Studies.

Date: December 5, 2000.

Time: 7:30 am to 6 pm.

Agenda: to review and evaluate grant

applications.

Place: The Handlery Union Square Hotel,

351 Geary Street, San Francisco, CA 94102.

Contact Person: Martin H. Goldrosen, PhD,

Scientific Review Administrator, Grants

Review Branch, Division of Extramural

Activities, National Cancer Institute, National

Institutes of Health, 6116 Executive

Boulevard, Room 8050, Rockville, MD

20852–7408, (301) 496–7930.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: November 3, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–29141 Filed 11–14–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Center for Complementary

and Alternative Medicine; Notice of

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the National Advisory

Council for Complementary and

Alternative Medicine (NACCAM).

The meeting will be open to the

public as indicated below, with

attendance limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications

and/or contract proposals and the

discussions could disclose confidential

trade secrets or commercial property

such as patentable material, and

personal information concerning

individuals associated with the grant

applications and/or contract proposals,

the disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Advisory

Council for Complementary and Alternative

Medicine.

Date: November 13, 2000.

Open: 8:30 am to 2 pm.

Agenda: The agenda includes the

Director’s Report, a presentation on Proposed

Program Initiatives, Public Comments, and

other business of the Council.

Closed: 2 pm to adjournment.

Agenda: To review and evaluate grant

applications and/or proposals.

Place: NIH Neuroscience Office Building,

6001 Executive Blvd., Rockville, MD 20892.

Contact Person: Richard Nahin, Ph.D.,

Executive Secretary, National Center for

Complementary and Alternative Medicine,

National Institutes of Health, 6707

Democracy Blvd., Suite 106, Bethesda, MD

20892, 301/496–4792.

The public comments session is scheduled

from 1:30–2 pm. Each speaker will be

permitted 5 minutes for their presentation.

Interested individuals and representatives of

organizations are requested to notify Dr.

Richard Nahin, National Center for

Complementary and Alternative Medicine,

NIH, 6707 Democracy Boulevard, Suite 106,

Bethesda, Maryland, 20892, 301–496–4792,

Fax: 301–480–3621. Letters of intent to

present comments, along with a brief

description of the organization represented,

should be received no later than 5 pm on

November 8, 2000. Only one representative

of an organization may present oral

comments. Any person attending the meeting

who does not request an opportunity to speak

in advance of the meeting may be considered

for oral presentation, if time permits, and at

the discretion of the Chairperson. In

addition, written comments may be

submitted to Dr. Nahin at the address listed

above up to ten calendar days (November 23,

2000) following the meeting.

Copies of the meeting agenda and the

roster of members will be furnished upon

request by Dr. Richard Nahin, Executive

Secretary, NACCAM, National Institutes of

Health, 6707 Democracy Boulevard, Suite

106, Bethesda, Maryland 20892, (301) 496–

4792, Fax 301–480–3621.

This notice is being published less than 15

days prior to the meeting due to scheduling

conflicts.

Dated: November 1, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy, NIH.

[FR Doc. 00–29131 Filed 11–14–00; 8:45 am]

BILLING CODE 4140–01–M